Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b Open-label Study of Lazertinib Alone or with Amivantamab ± Chemotherapy in Advanced EGFR-mutated NSCLC
jRCT2080224850Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of lazertinib and amivantamab in EGFR-mutated non-small cell lung cancer and non-small cell lung cancer (NSCLC) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of lazertinib monotherapy, Pharmacokinetics of lazertinib and 1 more. Started Sep 2019; status: completed.
02
Drugs
lazertinibamivantamab
03
Conditions
EGFR-mutated non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224850.